University of California

Other

Harvard College

University of Washington

Xoma Corporation

David S Eisenberg

Edward M Marcotte

Lin Jiang

Todd O Yeates

Matteo Pellegrini

Michael J Thompson

Dennis J Slamon

R John Collier

Ralf Landgraf

Elizabeth Singer

Smriti Sangwan

Alice Soragni

Seunghyon Choe

David Baker

Stephen Fitzhugh Carroll

Richard L Gallo

Stuart A Sievers

Robert L Modlin

James U Bowie

Haian Fu

Jenny J Kim

Melinda Balbirnie

Wei Hai Shen

John Karanicolas

Lorena Saelices Gomez

Daniel H Anderson

Paul M Seidler

Sergio H Rotstein

David R Boyer

Robert Grothe

Daniel Fischer

Lesa J Beamer

Roland Luthy

An extensible display screen apparatus includes a power supply device and a screen display device. The screen display device includes at least one screen unit and a screen support assembly, wherein the at least one screen unit is disposed on the screen support assembly and the screen support assembly is arranged to support the at least one screen unit, whereas the at least one screen support assembly can electrically connect with the screen display device through the power supply device. The power supply device is configured to provide a working power to the at least one screen unit for a mobile electronic device to communicate with the at least one screen unit, wherein the said screen unit provides additional information of the mobile electronic device while being electrically connected with the screen display device.

Extensible display screen apparatus for mobile electronic device

This invention relates to inhibitory peptides which bind to &#x3b1;-synuclein molecules and inhibit &#x3b1;-synuclein amyloidogenic aggregation, &#x3b1;-synuclein cytotoxicity, and spread of &#x3b1;-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by &#x3b1;-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

Structure-based peptide inhibitors of &#x3b1;-synuclein aggregation

The invention disclosed herein relates to peptide inhibitors for transthyretin (TTR) aggregation and methods of inhibiting TTR aggregation, cytotoxicity, and/or TTR amyloidosis. Illustrative embodiments of the invention include a composition of matter comprising at least one peptide designed to inhibit the aggregation of TTR, with this peptide typically being coupled to a heterologous amino acid tag. A pharmaceutically acceptable carrier selected to be compatible with the inhibitory peptide may also be included. A method for blocking or inhibiting the aggregation of transthyretin TTR is also provided. The method comprises combining TTR with an effective amount of an inhibitory peptide or pharmaceutical composition, so that TTR aggregation and/or cytotoxicity is blocked or inhibited.

Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments

Aggregated Tau protein is associated with over 20 neurological disorders including Alzheimer's disease. Previous work has shown that Tau's sequence segments VQIINK (SEQ ID NO: 11) and VQIVYK (SEQ ID NO: 9) drive its aggregation, and that inhibitors based on the structure of the VQIVYK (SEQ ID NO: 9) segment partially inhibit Tau aggregation. Here we show that the VQIINK (SEQ ID NO: 11) segment is the more powerful driver of Tau aggregation. Two structures of this segment determined by the cryo EM method MicroED explain its more powerful seeding. Of practical significance, the understanding of the structures has led to the design of structure based peptide inhibitors that effectively inhibit Tau aggregation as well as the ability of exogenous Tau fibrils to seed intracellular Tau in mammalian cells into amyloid.

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

Structure-based peptide inhibitors of alpha-synuclein aggregation

This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

A multiple screen arrangement for a mobile device that includes a screen module and a communication module for communicatively linking the screen module with the mobile device. The screen module includes first and second screens movably coupled with each other between a first state and a second state, wherein at the first state, the second screen is overlapped behind the first screen in a single screen size manner, and at the second state, the first and second screens are moved side-by-side to provide two viewing windows. The communication module is adapted for receiving data from the mobile device to be displayed on at least one of the first and second screens, such that the first and second screens are adapted for selectively displaying the data from the mobile device between the first state and said second state.

Multiple screen arrangement for mobile device

Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a &#x3b2;-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the &#x3b2;-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.

Dissolution of amyloid fibrils by flavonoids and other compounds

The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms energetically-favorable interactions with the amino acid sequence of the steric zipper region of the target protein, and also possess a zipper-disrupting feature that disrupt the peptide stacking at the steric zipper region. This method can be used to obtain inhibitory peptides to disrupt fibril formation involving any protein for which a steric zipper sequence can be identified. The invention also provides inhibitory peptidic compounds, which can be used in pharmaceutical compositions and methods for treating polypeptide aggregation-associated diseases or conditions.

Structure-based design of peptide inhibitors of amyloid fibrillation

Granulysin peptides are small antimicrobial agents with potent activity against bacteria and inflammation. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient suffering from a microbial infection.

Granulysin peptides and methods of use thereof

The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include HER3 variant polypeptides having amino acid sequences which differ from the native HER3 polypeptide sequence and which have altered affinities for heregulin. Also disclosed herein are methods and materials for identifying compounds that bind to the heregulin binding domain in HER3 as well as methods and materials for modulating the interaction between HER3 and heregulin.

Methods and materials for characterizing and modulating interaction between heregulin and HER3

The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include methods for identifying compounds which specifically bind the heregulin binding domain in HER3.

The invention provides novel methods for characterizing the function of nucleic acids and polypeptides. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism. The characterization is based on use of methods of the invention comprising algorithms that can identify functional relationships between diverse sets of non-homologous nucleic acid and polypeptide sequences. The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism. The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug. The invention provides a computer system, comprising a processor and a computer program product of the invention.

Determining the functions and interactions of proteins by comparative analysis

A computational method system, and computer program are provided for inferring functional links from genome sequences. One method is based on the observation that some pairs of proteins A&prime; and B&prime; have homologs in another organism fused into a single protein chain AB. A trans-genome comparison of sequences can reveal these AB sequences, which are Rosetta Stone sequences because they decipher an interaction between A&prime; and B. Another method compares the genomic sequence of two or more organisms to create a phylogenetic profile for each protein indicating its presence or absence across all the genomes. The profile provides information regarding functional links between different families of proteins. In yet another method a combination of the above two methods is used to predict functional links.

Growing community of inventors

Los Angeles, CA, United States of America

David S Eisenberg